Bio-ADM, the very first blood biomarker capable to diagnose when blood vessels become leaky (endothelial dysfunction), is set to make a rapid carrier at intensive care units (ICUs) and emergency departments (EDs) of hospitals. Data from pilot clinical routine testing presented at the 2nd Scientific Symposium on Endothelial Disruption (18. December 2018) in Berlin impressively confirmed results from previous tests on 30,000 patients with acute heart failure (AHF) and severe sepsis indicating that bio-ADM testing improves medical decision making to prevent mortality, organ damage and rehospitalisation. An automated point-of-care (POC) test measuring bio-ADM both as a biomarker and as a companion diagnostic to a therapeutic antibody (adrecizumab) that repairs endothelial dysfunction, will be launched by H1/2019 by Sphingotec GmbH. However, bio-ADM is just the first representative of a full pipeline of diagnostic blood proteins reflecting disturbed signalling pathways underlying disorders of unmet medical need.
Endothelial disruption: From bench to bedside
BackgroundBio-ADM, the very first blood biomarker capable to diagnose when blood vessels become leaky (endothelial dysfunction), is set to make a rapid carrier at intensive care units (ICUs) and emergency departments (EDs) of hospitals. Data from pilot clinical routine testing presented at the 2nd Scientific Symposium on Endothelial Disruption (18. December 2018) in Berlin impressively confirmed results from previous tests on 30,000 patients with acute heart failure (AHF) and severe sepsis indicating that bio-ADM testing improves medical decision making to prevent mortality, organ damage and rehospitalisation. An automated point-of-care (POC) test measuring bio-ADM both as a biomarker and as a companion diagnostic to a therapeutic antibody (adrecizumab) that repairs endothelial dysfunction, will be launched by H1/2019 by Sphingotec GmbH. However, bio-ADM is just the first representative of a full pipeline of diagnostic blood proteins reflecting disturbed signalling pathways underlying disorders of unmet medical need.
Sanofi ends immuno-oncology discovery with Regeneron
Latest NewsSanofi and Regeneron announced they have "restructured" their US$2,17bn immunoncology collaboration. While the companies will continue co-marketing of the FDA approved (2018) PD1 blocker cemiplimab (REGN2810) as treatment for cutaneous squamous cell carcinoma, Sanofi will quit development of early stage antibody discovery programmes under the 2015 agreement.
Goodfellow helps international companies facilitate industrial innovation
Sponsored PublicationsLeading global supplier of materials, Goodfellow, has collaborated with a number of major international companies to provide research materials in several industry sectors.
Diverse cells make up the endothelium
Latest NewsCells that line the blood vessels do not behave identically but instead exhibit varied responses to the same biochemical signals, British researchers report in Science.
Microbiome defines gut conditions
Latest NewsDifferences in microbiome composition can help to distinguish inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), Dutch and US researchers report.
Cellestia Biotech AG attracts Series A financing
Latest NewsCancer specialist Cellestia Biotech AG has secured CHF20m through a Series A financing led by FC Capital, and PPF / Sotio, and ETP Ventures, Boston & Beijing.
Staten Biotechnology in $430m deal with Novo Nordisk
Latest NewsStaten Biotechnology has signed a dyslipidaemia licence option deal worth US$430m with Novo Nordisk.
Kurma Partners announce closing of Biofund III
Latest NewsParis-based Kurma Partners announced the first closing of its Kurma Biofund III, a life science fund set to raise €150m.
MEPs back €120bn budget for Horizon Europe
Latest NewsThe European Parliament has voted to add €36.5bn to the budget of Horizon Europe (€94.1bn, in 2018 prices) proposed by the European Commission to foster research and innovation.
New cheap CRS-blockers at the horizon
Latest NewsCancer immunotherapies are often associated with severe cytokine release syndrome (CRS) that can be managed with IL-6R-blockers. US oncologists now report that an FDA-approved hypertension drug did the same job as Roche’s anti-IL-6R blocker tocolizumab.